Oct 22, 2018 • 8:00 am EDT Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
Oct 18, 2018 • 4:05 pm EDT Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
Oct 3, 2018 • 9:00 am EDT Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
Sep 26, 2018 • 8:00 am EDT Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
Sep 20, 2018 • 7:00 am EDT Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study
Sep 18, 2018 • 8:05 am EDT Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
Sep 14, 2018 • 8:05 am EDT Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
Aug 23, 2018 • 8:05 am EDT Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
Aug 8, 2018 • 9:00 am EDT Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
Jul 25, 2018 • 9:20 am EDT Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis